Novo Nordisk's Q2 Performance Highlights

Novo Nordisk A/S has announced a robust 13% increase in total sales for the second quarter of fiscal 2025, reaching 76.9 billion Danish kroner ($11.9 billion), aligning with analysts' expectations. The company also reported a significant 32% annual increase in net profit, totaling 26.5 billion Danish kroner, with diluted earnings per share (EPS) jumping by 33% to 5.96 Danish kroner.

Revised Full-Year Outlook

The maker of Ozempic has adjusted its full fiscal 2025 guidance downward, now anticipating sales growth in Danish kroner to be three percentage points lower than the previously expected 8%-10% growth at Constant Exchange Rates (CER). This revision is primarily due to reduced growth expectations for Wegovy and Ozempic in the US market.

CEO's Statement on Strategic Adjustments

"Despite achieving an 18% sales growth in the first half of 2025, we've revised our full-year outlook due to lower growth projections for our GLP-1 treatments in the latter half of the year. In response, we're implementing measures to enhance our commercial execution, optimize our cost base, and continue investing in future growth opportunities," stated CEO Lars Fruergaard Joergensen.